Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 4Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
naquotinib × Thoracic × Clear all
NCT02588261 2024-12-10

SOLAR

Astellas Pharma Inc

Phase 3 Terminated
530 enrolled 25 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02500927 2024-11-20

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Astellas Pharma Inc

Phase 2 Terminated
31 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03082300 2024-11-20

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Astellas Pharma Inc

Phase 1 Terminated
3 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02113813 2024-11-14

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Astellas Pharma Inc

Phase 1 Completed
133 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02192697 2024-11-14

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Astellas Pharma Inc

Phase 1/2 Terminated
124 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03042013 2017-07-11

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Astellas Pharma Inc

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡